Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Hua Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125055

2024-01-01

Abstract:Supplementary Video S1 is related to Figure 5 (Vehicle-only group).

What problem does this paper attempt to address?

Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Hua Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125055.v1

2024-01-01

Abstract:Supplementary Video S1 is related to Figure 5 (Vehicle-only group).
Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125052.v1

2024-01-01

Abstract:Supplementary Video S2 is related to Figure 5 (Olaparib-only group).
Supplemental Table S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125061

2024-01-01

Abstract:Metabolomics of primary tumors vs bone metastasis
Supplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.25125064

2024-01-01

Abstract:Metabolomics of macrophages vs osteaoclasts
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Wenqun Zhong,Zebin Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23907869

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Data from an Alternatively Spliced P62 Isoform Confers Resistance to Chemotherapy in Breast Cancer

Qianying Guo,Hao Wang,Jiahao Duan,Wenwu Luo,Rongrong Zhao,Yuting Shen,Bijun Wang,Siqi Tao,Yi Sun,Qian Ye,Xiaomin Bi,Hui Yuan,Qiang Wu,Peter E. Lobie,Tao Zhu,Sheng Tan,Xing Huang,Zhengsheng Wu

DOI: https://doi.org/10.1158/0008-5472.22432764.v1

2023-01-01

Abstract:Supplementary Data from An Alternatively Spliced p62 Isoform Confers Resistance to Chemotherapy in Breast Cancer
Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.CAN-23-1443

2024-02-01

Abstract:The majority of patients with late-stage breast cancer develop distal bone metastases. The bone microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating bone metastatic breast cancer. Here, we observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation enhanced the survival of breast cancer cells treated with DNA damaging agents, while blocking glutamine uptake increased sensitivity and suppressed bone metastasis. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated in cancer cells following PARPi treatment through stress-induced ATF4-dependent transcriptional programming. Increased glutamine uptake and GPX4 upregulation concertedly enhanced glutathione metabolism in cancer cells to help neutralize oxidative stress and generate PARPi resistance. Analysis of paired patient samples of primary breast tumors and bone metastases revealed significant induction of GPX4 in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generated a synergistic effect in reducing bone metastasis. These results identify a role for glutamine production by bone-resident cells in supporting metastatic cancer cells to overcome oxidative stress and develop resistance to DNA-damaging therapies. Significance: Metabolic interaction between osteoclasts and tumor cells contributes to resistance to DNA-damaging agents, which can be blocked by combination treatment with PARP and osteoclast inhibitors to reduce bone metastatic burden.
Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528434.v1

2023-01-01

Abstract:<p>PDF file, 81K, Effect of PARP inhibition in combination with standard chemotherapy.</p>
Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1158/0008-5472.can-23-1443

IF: 11.2

2023-12-02

Cancer Research

Abstract:The majority of patients with late-stage breast cancer develop distal bone metastases. The bone microenvironment can affect response to therapy, and uncovering the underlying mechanisms could help identify improved strategies for treating bone metastatic breast cancer. Here, we observed that osteoclasts reduced the sensitivity of breast cancer cells to DNA damaging agents, including cisplatin and the PARP inhibitor (PARPi) olaparib. Metabolic profiling identified elevated glutamine production by osteoclasts. Glutamine supplementation enhanced the survival of breast cancer cells treated with DNA damaging agents, while blocking glutamine uptake increased sensitivity and suppressed bone metastasis. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated in cancer cells following PARPi treatment through stress-induced ATF4-dependent transcriptional programming. Increased glutamine uptake and GPX4 upregulation concertedly enhanced glutathione metabolism in cancer cells to help neutralize oxidative stress and generate PARPi resistance. Analysis of paired patient samples of primary breast tumors and bone metastases revealed significant induction of GPX4 in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generated a synergistic effect in reducing bone metastasis. These results identify a role for glutamine production by bone-resident cells in supporting metastatic cancer cells to overcome oxidative stress and develop resistance to DNA-damaging therapies.

oncology
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Supplementary Video 1 from Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1α/CXCR4 Axis

Nan Song,Yujie Huang,Hubing Shi,Shaopeng Yuan,Yanping Ding,Xiaomin Song,Yan Fu,Yongzhang Luo

DOI: https://doi.org/10.1158/0008-5472.22377597

2023-01-01

Abstract:Supplementary Video 1 from Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1α/CXCR4 Axis
Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497787

2023-01-01

Abstract:PDF file - 63K, Figure S1: Expression of RON and MET by breast cancer MCF-7, T-47D and ZR-75-1 cells.
Osteoclast-Cancer Cell Metabolic Symbiosis Renders PARP Inhibitor Therapy Resistance in Bone Metastasis

Huijuan Fan,Zhanao Xu,Ke Yao,Bingxin Zheng,Yuan Zhang,Xuxiang Wang,Tengjiang Zhang,Xuan Li,Haitian Hu,Bin Yue,Zeping Hu,Hanqiu Zheng

DOI: https://doi.org/10.1101/2023.08.15.553338

2023-01-01

Abstract:Seventy percent of patients with late-stage breast cancer develop distal bone metastases; however, the mechanism by which the metabolic microenvironment affects resistance to therapy remains unknown. We investigated the metabolic bone microenvironment and identified glutathione metabolism as the top pathway in osteoclasts, which provides feedback to tumor cells to help neutralize oxidative stress and generate PARP inhibitor (PARPi) therapy resistance. GPX4, the critical enzyme responsible for glutathione oxidation, was upregulated during PARPi therapy through stress-induced ATF4-dependent transcriptional programming. The increased absorption of glutamine and the upregulation of GPX4 expression work in concert to enhance glutathione metabolism in cancer cells. Human clinical sample analysis of paired primary breast tumor and bone metastasis samples revealed that GPX4 was significantly induced in bone metastases. Combination therapy utilizing PARPi and zoledronate, which blocks osteoclast activity and thereby reduces the microenvironmental glutamine supply, generates a synergistic effect in reducing bone metastasis. Thus, our results identified an essential metabolic symbiosis between bone-resident cells and metastatic cancer cells during PARPi therapy. SIGNIFICANCE Osteoclast-derived glutamine is taken up by tumor cells to synthesize glutathione and neutralize the ROS generated by PARPi. This is the first example of “metabolic symbiosis” in therapeutic resistance of bone metastasis. ### Competing Interest Statement The authors have declared no competing interest.
Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497784.v1

2023-01-01

Abstract:PDF file - 68K, Figure S2: Effect of BMS-777607 on breast cancer cell growth and apoptotic death.
Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419837.v1

2023-01-01

Abstract:Supplementary figure S5. DAC treatment did not increase the risk of osteosarcoma proliferation.
Supplementary Figure 3 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Sharad Sharma,Junying Zeng,Chun-Mei Zhuang,Yong-Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming‐Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22497781

2023-01-01

Abstract:PDF file - 59K, Figure S3: Effect of PHA665752, Compound-I, and BMS-777607 on induction of polyploidy in breast cancer cells.
Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419828

2023-01-01

Abstract:Supplementary Table S2. Patient characteristics
Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Dan Su,Ruobing Wang,Guangyu Chen,Chen Ding,Yueze Liu,Jinxin Tao,Yuanyang Wang,Jiangdong Qiu,Wenhao Luo,Guihu Weng,Gang Yang,Taiping Zhang

DOI: https://doi.org/10.1158/0008-5472.26711161.v1

2024-01-01

Abstract:Supplementary Fig. S5
Supplementary Figure 1 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer

Jeroen T. Buijs,Nico V. Henriquez,Petra G.M. van Overveld,Geertje van der Horst,Ivo Que,Ruth Schwaninger,Cyrill Rentsch,Peter ten Dijke,Anne-Marie Cleton-Jansen,Keltouma Driouch,Rosette Lidereau,Richard Bachelier,Slobodan Vukicevic,Philippe Clézardin,Socrates E. Papapoulos,Marco G. Cecchini,Clemens W.G.M. Löwik,Gabri van der Pluijm

DOI: https://doi.org/10.1158/0008-5472.22366266.v1

2023-01-01

Abstract:Supplementary Figure 1 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer
Supplementary Figure 2 from CD47 Regulates Bone Mass and Tumor Metastasis to Bone

Özge Uluçkan,Stephanie N. Becker,Hongju Deng,Wei Zou,Julie L. Prior,David Piwnica-Worms,William A. Frazier,Katherine N. Weilbaecher

DOI: https://doi.org/10.1158/0008-5472.22379954.v1

2023-01-01

Abstract:Supplementary Figure 2 from CD47 Regulates Bone Mass and Tumor Metastasis to Bone

Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplemental Table S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Data from an Alternatively Spliced P62 Isoform Confers Resistance to Chemotherapy in Breast Cancer

Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Osteoclast-Cancer Cell Metabolic Crosstalk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Video 1 from Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1α/CXCR4 Axis

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Osteoclast-Cancer Cell Metabolic Symbiosis Renders PARP Inhibitor Therapy Resistance in Bone Metastasis

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Figure S5 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure 3 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Table S2 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Fig. S5 from FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis

Supplementary Figure 1 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer

Supplementary Figure 2 from CD47 Regulates Bone Mass and Tumor Metastasis to Bone